Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Usefulness and Tolerability of Postoperative Adjuvant Chemotherapy for Colorectal Cancer in the Elderly

ABSTRACT: Primary outcome(s): Relapse-free survival Overall survival Safety Tolerability Recurrence rate

DISEASE(S): Colorectal Cancer

PROVIDER: 2740980 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Usefulness of postoperative adjuvant chemotherapy in patients with colorectal cancer T1/T2, N(+)

Project description:Primary outcome(s): overall survival relapse-free survival disease-free survival Time-to-treatment-failure

| 2725001 | ecrin-mdr-crc

Association between adverse events and prognosis in postoperative adjuvant chemotherapy for colorectal cancer

Project description:Primary outcome(s): Relapse-free survival Overall survival Adverse event Compliance

| 2740981 | ecrin-mdr-crc

Postoperative complications of colorectal cancer and their impact on postoperative adjuvant chemotherapy and prognosis

Project description:Primary outcome(s): overall survival relapse-free survival disease-free survival Time-to-treatment-failure Compliance Relative Dose Intensity Percentage of drug treatment discontinuation, dose reduction and drug suspension

| 2725003 | ecrin-mdr-crc

Transcription profiling of human NSCLC samples to predict recurrence-free survival in postoperative nsclc patients

Project description:Background:; One of the main fields of lung cancer research is identifying patients who are at high risk of post-resection recurrence. Individual recurrence risk evaluation by accurate but simple and reproducible method is needed for the clinical practice. Results:; The log-rank test and further selection by our criteria of assayability generated 87 genes from microarray data with significant level 5%. Of these, by PTQ-PCR, the expression of most significant 18 genes was obtained. Using these gene expression information and clinical parameters, by stepwise variable selection method, the recurrence prediction model, which composed of 6 genes (CALB1, MMP7, SLC1A7, GSTA1, CCL19, IFI44) and pStage and cell differentiation, were developed. Validation into the two independent cohorts showed good results of the proposed model (p=0.0314, 0.0305, respectively). The predicted median recurrence-free survival times for each patient were reflected real ones well. Conclusions:; Our method of individualized recurrence risk prediction is accurate, technically simple and reproducible to be used in clinical practice. Therefore, it would be useful in customizing the lung cancer management strategies. Experiment Overall Design: Methods: Experiment Overall Design: At first, we selected the statistically significant genes from the analysis of time-to-recurrence and censoring information from 138 whole-genome wide microarray data. Then, we further reduced the number of genes which could be reliably reproducible by RTQ-PCR. With these assayable genes and clinical parameters, construction of recurrence prediction model by Cox proportional hazard regression was done. After validation into two independent cohorts (n=59 and n=56), the model was transformed into recurrence prediction for the each patient.

2008-06-17 | E-GEOD-8894 | biostudies-arrayexpress

A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)

Project description:This is a controlled study designed to compare relapse-free survival and overall survival in patients receiving UFT with those in patients receiving surgery alone. Patients will be randomly assigned to surgery alone or surgery followed by UFT within 6 weeks after curative resection. To assess treatment efficacy, data on recurrence and survival will be collected for 5 years after enrollment of the last patient. To evaluate safety, data on adverse events will be collected for 12 months after the start of treatment.Evaluations will be separately done for colon cancer and rectal cancer.

| 2015919 | ecrin-mdr-crc

Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients—a Useful Prospective Clinical Practice

Project description:Background: One of the main fields of lung cancer research is identifying patients who are at high risk of post-resection recurrence. Individual recurrence risk evaluation by accurate but simple and reproducible method is needed for the clinical practice. Results: The log-rank test and further selection by our criteria of assayability generated 87 genes from microarray data with significant level 5%. Of these, by PTQ-PCR, the expression of most significant 18 genes was obtained. Using these gene expression information and clinical parameters, by stepwise variable selection method, the recurrence prediction model, which composed of 6 genes (CALB1, MMP7, SLC1A7, GSTA1, CCL19, IFI44) and pStage and cell differentiation, were developed. Validation into the two independent cohorts showed good results of the proposed model (p=0.0314, 0.0305, respectively). The predicted median recurrence-free survival times for each patient were reflected real ones well. Conclusions: Our method of individualized recurrence risk prediction is accurate, technically simple and reproducible to be used in clinical practice. Therefore, it would be useful in customizing the lung cancer management strategies. Keywords: Recurrence Free Survival Analysis

2007-11-20 | GSE8894 | GEO

Homo sapiens

Project description:A novel five-gene signature predicts overall and recurrence-free survival in NSCLC

| PRJNA156819 | ENA

RNA seq from GBM cell lines and primary cultures after irradiation

Project description:Glioblastoma is the most common, aggressive tumor of CNS, with a 5-year overall survival rate of 5%. The treatment is challenging due to its location and the inevitable recurrence in 80% of the cases. To understand the cause behind this recurrence, we established an in vitro radiation survival model that mimics clinical scenarios. GBM Parent (P) cells, after being given a lethal dose of radiation, undergo tremendous cell death but leave behind a small residual surviving population that shows senescence phenotype. These residual (RS) cells eventually reverse from senescence (End of senescence) and give rise to aggressive relapse (R). To find molecular players behind this reversal of senescence, we carried out RNA sequencing of GBM cell lines U87MG and SF268 at mentioned stages of senescence post-radiation treatment.

2026-02-08 | E-MTAB-13786 | biostudies-arrayexpress

RNA-seq of in vitro radio-resistant human GBM cell line (LN229) and patient-derived culture (PS1) post YBX3 knockdown

Project description:Glioblastoma (GBM)is the most aggressive brain tumor with poor overall survival due to high recurrence rate. The recurrent GBM tumors are highly aggressive and resistant to therapy. In the current study, we explored the potential role of Y-box binding protein 3 (YBX3) in glioblastoma aggressiveness. We found significantly high expression of YBX3 in GBM compared to low-grade glioma, and the expression of YBX3 significantly correlated with poor overall and disease-free survival of GBM patients. Knockdown of YBX3 in established GBM primary cultures and cell line abrogated the invasion and migration of GBM cells in vitro, and tumorigenicity and metastasis in vivo. Further, we found high expression of YBX3 in the recurrent GBM patient biopsies. To decipher the genes and biological pathways by which YBX3 regulates the GBM aggressiveness, we performed RNA-Seq experiment on LN229-Relapse and patient-derived primary culture relapse cells (PS1) after stable knockdown of YBX3.

2025-12-21 | E-MTAB-14224 | biostudies-arrayexpress

Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis

Project description:Primary outcome(s): The primary endpoint was long-term survival including overall survival (OS) and recurrence/relapse-free survival (RFS).

| 2654299 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data